Irmak Duygu Koyuncu, Darıcı Hakan, Karaöz Erdal
1Istinye University, Faculty of Medicine, Department of Histology & Embryology, Istanbul, Turkey.
2Istinye University, Stem Cell and Tissue Engineering R&D Center, Istanbul, Turkey.
Aging Dis. 2020 Oct 1;11(5):1174-1191. doi: 10.14336/AD.2020.0608. eCollection 2020 Oct.
The COVID-19 patients were first detected in China, in December 2019, then the novel virus with associated pneumonia and other diseases spread quickly to worldwide becoming a serious public health intimidation. Despite all the efforts, the pharmacological agents used for controlling or treating the disease, especially respiratory problems, have not been accomplished so far. Among various treatment options, mesenchymal stem cell-based cellular therapies are being investigated, because of their regeneration ability and multipotency along with other features like immunomodulation, antifibrosis and anti-inflammatory effects. This paper intends to analyze the current clinical trials on stem cell treatment of novel virus, searching and reviewing the available information and the International Clinical Trials Registry Platform (ICTRP) of World Health Organization (WHO). We concluded that the stem cell treatment of COVID-19 is found promising with pilot studies' results, but still in the early development phase. There is an urgent need for large-scale investigations to confirm and validate the safety and efficacy profile of these therapies with reliable scientific evidence.
2019年12月，中国首次检测到新冠病毒患者，随后这种伴有肺炎和其他疾病的新型病毒迅速蔓延至全球，成为严重的公共卫生威胁。尽管付出了种种努力，但目前用于控制或治疗该疾病，尤其是呼吸系统问题的药物尚未取得成效。在各种治疗方案中，基于间充质干细胞的细胞疗法因其再生能力、多能性以及免疫调节、抗纤维化和抗炎等其他特性而正在被研究。本文旨在分析目前关于新型病毒干细胞治疗的临床试验，检索并综述世界卫生组织（WHO）国际临床试验注册平台（ICTRP）的可用信息。我们得出结论，从初步研究结果来看，新冠病毒的干细胞治疗前景乐观，但仍处于早期开发阶段。迫切需要进行大规模研究，以可靠的科学证据证实并验证这些疗法的安全性和有效性。
